Gilead Sciences retains regular Real Value of USD88.67 per share. The prevalent price of the corporation is USD71.01. At this time the corporation appears to be under valued. Macroaxis calculates value of Gilead Sciences from evaluating the corporation fundamentals such as Current Valuation of 111.07B, Return On Asset of
22.43% and Return On Equity of 85.39% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.
Valuation Drivers Correlation
|Investment Horizon||30 Days Login to change|
Gilead Sciences Total Value AnalsysGilead Sciences Inc is currently projected to have valuation of 111.07 B with market capitalization of 96.27 B, debt of 27.07 B, and cash on hands of 12.27 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gilead Sciences fundamentals before making equity appraisal based on the enterprise value of the company
Gilead Sciences Investor InformationAbout 83.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 10.82. Gilead Sciences Inc last dividend was issued on December 13, 2016. This company had 2:1 split on January 28, 2013. Gilead Sciences Inc., a researchbased biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the AsiaPacific. To learn more about GILEAD SCIENCES call John Martin at 650-574-3000 or check out http://www.gilead.com.
Gilead Sciences Asset UtilizationGilead Sciences harnesses its working resources almost 22.43 (percent), generating USD0.2243 for each dollar of working resources held by the corporation. An expanding assets utilization attests that the company is being more effective with each dollar of working resources it retains. In other words assets utilization of Gilead Sciences shows how effective it operates for each dollar spent on its working resources
Gilead Sciences Ownership Allocation (%)Gilead Sciences secures a total of 1.32 Billion outstanding shares. Majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investers are referred to non-private investors that are looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to different set of regulations than regular investors in Gilead Sciences Inc. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or about to change at the company. Note that regardless of how profitable the company is, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns from it at some point.
Gilead Sciences Profitability AnalysisThe company reported previous year revenue of 31.58 B. Net Income was 15.08 B with profit before overhead, payroll, taxes, and interest of 28.63 B.
Gilead Sciences is not too risky asset. Calculation of real value of Gilead Sciences is based on 1 month time horizon. Increasing Gilead Sciences time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.